Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00069901 · ClinicalTrials.gov registry record · Phase 2
Phase II CT-2103/Carboplatin in Ovarian Cancer
A Phase 2 study, sponsored by CTI BioPharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 82
- Enrollment target
NCT00069901: Completed Phase 2 study, sponsored by CTI BioPharma.
NCT00069901 is a Phase 2 study that has completed, run by CTI BioPharma. The registered enrollment target is 82 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00069901, a Phase 2 study, has completed, sponsored by CTI BioPharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 82 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of CT-2103 (poly(L)glutamate-paclitaxel) in combination with carboplatin for the treatment of patients with Stage III or IV ovarian or primary peritoneal cancer.
Interventions
- DRUG carboplatin
- DRUG CT-2103 (poly(L)glutamate-paclitaxel)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2003-02 |
| Est. Completion | 2006-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00069901
The ClinicalTrials.gov registry entry for NCT00069901 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CTI BioPharma, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which carboplatin is the first listed.
NCT00069901 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00069901 about?
NCT00069901 is a clinical study titled "Phase II CT-2103/Carboplatin in Ovarian Cancer". The purpose of this study is to evaluate the safety and efficacy of CT-2103 (poly(L)glutamate-paclitaxel) in combination with carboplatin for the treatment of patients with Stage III or IV ovarian or primary peritoneal cancer.
What is the current status of trial NCT00069901?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 82 participants. The study started on 2003-02. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00069901?
The interventions under investigation include: carboplatin (DRUG), CT-2103 (poly(L)glutamate-paclitaxel) (DRUG).
Who is sponsoring clinical trial NCT00069901?
This trial is sponsored by CTI BioPharma, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.